BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Yin L, Liu K, Lv W, Xu S, Lu D, Zhou C, Cheng D, Gao Z, Shi C, Su M. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation. DDDT 2022;Volume 16:3421-3429. [DOI: 10.2147/dddt.s372276] [Reference Citation Analysis]
2 Hui F, Xu C, Xu X, Chen J, Geng H, Yang C, Zhang Y. What Is the Most Suitable Agent Combined With Apatinib for Transarterial Chemoembolization Treatment in Advanced Hepatocellular Carcinoma Patients? A Systematic Review and Network Meta-analysis. Front Oncol 2022;12:887332. [PMID: 35692745 DOI: 10.3389/fonc.2022.887332] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Chen R, Li L, Li Y, Song K, Shen C, Ma P, Wang Z. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study. J Gastrointest Oncol 2022;13:1367-75. [PMID: 35837188 DOI: 10.21037/jgo-22-525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ju S, Wang W, Chen P, Li F, Li H, Wang M, Han X, Ren J, Duan X. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C. Clin Res Hepatol Gastroenterol 2022;:101859. [PMID: 34999249 DOI: 10.1016/j.clinre.2022.101859] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ouyang T, Liu J, Shi C, Zhu L, Guo X. Drug-Eluting Bead Transarterial Chemoembolization versus Conventional Transarterial Chemoembolization Both Combined Apatinib for Hepatocellular Carcinoma: A Retrospective, Propensity-Score Matched Study. J Hepatocell Carcinoma 2021;8:1459-71. [PMID: 34858890 DOI: 10.2147/JHC.S338309] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Li Z, Chen Q, Zhang W, Si G, Li J, Jiao D, Han X. Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:5565793. [PMID: 34458205 DOI: 10.1155/2021/5565793] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 冯 源. Clinical Research Progress of Apatinib in the Treatment of Hepatocellular Carcinoma. ACM 2021;11:6195-6200. [DOI: 10.12677/acm.2021.1112919] [Reference Citation Analysis]